Helicobacter pylori LPS Specific Neutra™ Antibody Products

Are you struggling with lengthy therapeutic antibody development or inconsistent neutralization efficacy against Helicobacter pylori infections? Creative Biolabs’ H. pylori LPS specific Neutra™ antibody products leverage advanced epitope-specific engineering and validated functional assays to deliver high-affinity antibodies that precisely target lipopolysaccharide (LPS) virulence determinants, empowering robust translational research and therapeutic discovery.

Introduction to H. pylori LPS

Helicobacter pylori lipopolysaccharides (H. pylori LPS), a dominant surface antigen of this Gram-negative pathogen, play a central role in bacterial persistence and host immune evasion.

• Structural Insights

Structurally, H. pylori LPS comprises three domains: the O-antigen polysaccharide, core oligosaccharide, and lipid A. Unlike enterobacterial LPS, its lipid A moiety exhibits unique hypoacylation patterns (tetra-acylated), reducing recognition by Toll-like receptor 4 (TLR4) and enabling chronic gastric colonization. The O-antigen, often phase-variable, further diversifies antigenicity across strains, complicating diagnostic and therapeutic targeting.

• Pathogenic Mechanisms

The primary signaling pathway activated by H. pylori LPS involves pattern recognition receptors, albeit with unique engagement. Its atypical lipid A structure leads to weak TLR4 activation but can still engage other receptors like Toll-like receptor 2 (TLR2), triggering a subdued pro-inflammatory response. This altered signaling contributes to the persistent, low-grade gastric inflammation characteristic of H. pylori infection. The Lewis antigen mimics can also potentially interact with host lectins, modulating local immune cell activity and promoting a tolerogenic environment.

Fig.1 H. pylori LPS-mediated TLR4 signaling activation in gastric cancer.¹

• Disease Linkages

Chronic H. pylori infection is the major etiological agent for chronic active gastritis and peptic ulcer disease. It is the strongest identified risk factor for gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. The persistent inflammation driven by bacterial components, including LPS, leads to progressive damage to the gastric mucosa, ultimately resulting in severe clinical outcomes.

Applications of Anti-H. pylori LPS Neutralizing Antibodies

• Diagnostic Assay Development

Anti-LPS antibodies enable rapid, non-invasive detection of active H. pylori infection in stool or serum samples. Their high specificity supports differential diagnosis of strain-specific infections, critical for personalized treatment strategies.

• Vaccine Efficacy Evaluation

These antibodies serve as benchmarks for assessing vaccine-induced immune responses. By quantifying LPS-neutralizing titers, researchers optimize antigen design for next-generation prophylactic vaccines, aligning with global efforts to reduce gastric cancer burden.

• Mechanistic Studies of Immune Evasion

Antibodies facilitate detailed investigation of LPS-mediated immune suppression mechanisms, such as TLR2/4 crosstalk and T-regulatory cell activation, informing novel immunotherapies.

• Therapeutic Candidate Screening

In preclinical models, neutralizing antibodies reduce bacterial load and gastric inflammation, validating their utility as adjunctive therapies for antibiotic-resistant infections.

Our Anti-H. pylori LPS Antibodies

Creative Biolabs’ antibodies specifically neutralize H. pylori LPS by targeting conserved epitopes within lipid A or immunodominant O-antigen regions. These antibodies are rigorously validated for:

1. High Specificity: Minimal cross-reactivity with human or commensal microbiota antigens.

2. Functional Neutralization: Blocking LPS-induced proinflammatory cytokine release in vitro and in vivo models.

3. Diagnostic Versatility: Detection of diverse clinical isolates via ELISA, Western blot, or immunohistochemistry.

4. Therapeutic Potential: Disrupting bacterial adhesion and neutralizing endotoxin activity in preclinical studies.

Creative Biolabs offers H. pylori LPS specific Neutra™ antibody products, which are indispensable tools for researchers and developers tackling gastric pathogenicity. Engineered for unmatched specificity and neutralization potency, they accelerate diagnostic innovation, vaccine development, and therapeutic discovery. Contact our scientific team today to explore custom solutions for your H. pylori research or therapeutic projects.

REFERENCE

1. Ito, Nozomi, et al. "Helicobacter pylori-mediated immunity and signaling transduction in gastric cancer." Journal of clinical medicine 9.11 (2020): 3699. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/jcm9113699